Results 101 to 110 of about 103,385 (306)

Peripheral T Cell Non-Hodgkin’s Lymphoma following Treatment of Hodgkin’s Lymphoma

Case Reports in Oncological Medicine, 2015
Previous reports have suggested that non-Hodgkin’s lymphoma (NHL) is more likely to develop in patients with Hodgkin lymphoma (HL) compared to the general population. These two can occur synchronously or metachronously.
Sun Hee Chang, Hye Ran Lee
doaj   +1 more source

Multimodal Image Analysis of Chronic Leukemic Lymphoproliferative Disorders and the Hypothesis of »Single« and »Multiple« Programmed Stops in the Development of Typical and Atypical Forms of Leukemias and Lymphomas [PDF]

, 2010
The study consisted of morphometric analysis, assessment of the argyrophilic nucleolar organization region (AgNOR) characteristics, and image cytometry (ICM) in different tumor mass compartments: bone marrow (BM), peripheral blood (PB) and lymph nodes ...
Biljana Jelić Puškarić, Branimr Jakšić, Delfa Radić-Krišto, Ika Kardum-Skelin, Matko Kardum, Ozren Jakšić   +5 more
core   +2 more sources

Intraclonal diversity in a Sezary syndrome with a differential response to 2‐deoxycoformycin of the two lymphoma cell populations [PDF]

, 2002
Br J Haematol. 2002 Dec;119(3):629-33. Intraclonal diversity in a Sezary syndrome with a differential response to 2-deoxycoformycin of the two lymphoma cell populations.
BALANZATEGUI, A., CANDEIAS, J., CUNHA, N., GRANJO, E., LIMA, M., LOPES, J.M., MATUTES, E., ORFAO, A., RESENDE, C., SANTOS, A.H., SANTOS, F., TEIXEIRA, M. A.   +11 more
core   +1 more source

USP35 Acts as a Deubiquitinating Enzyme for ID3 to Promote Immune Escape in Colorectal Cancer

Advanced Science, EarlyView.
USP35 stabilizes ID3 expression by deubiquitinating the K2/K30 site, thereby upregulating PD‐L1 and promoting immune escape in colorectal cancer. IU1, an inhibitor of USP35 enzyme activity, has been shown to inhibit USP35, thereby accelerating ID3 degradation, enhancing CD8+ T cell killing, and reversing the immunosuppressive microenvironment ...
Wenxin Chen, Ling Wang, Hongmei Fan, Lisheng Li, Lingyu Zhang, Ruoxin Li, Fang Liu, Fuli Wen, Yunbin Ye, Chuanzhong Huang   +9 more
wiley   +1 more source

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas

Leukemia Research Reports
Brentuximab vedotin (BV) has demonstrated efficacy against CD30+ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV ...
Gen Hasegawa, Noriharu Nakagawa, Yoshimichi Ueda, Masahide Yamazaki   +3 more
doaj   +1 more source

Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified

Haematologica, 2018
Due to heterogeneous morphological and immunophenotypic features, approximately 50% of peripheral T-cell lymphomas are unclassifiable and categorized as peripheral T-cell lymphomas, not otherwise specified.
Meng-Meng Ji, Yao-Hui Huang, Jin-Yan Huang, Zhao-Fu Wang, Di Fu, Han Liu, Feng Liu, Christophe Leboeuf, Li Wang, Jing Ye, Yi-Ming Lu, Anne Janin, Shu Cheng, Wei-Li Zhao   +13 more
doaj   +1 more source

Intravascular Large B-Cell Lymphoma Presenting as Dementia and Hemolytic Anemia [PDF]

, 2010
Background: Intravascular lymphoma (IVL) is an uncommon disease characterized by atypical lymphoid cells growing inside the lumina of small vessels. The diversity of clinical presentation due to possible involvement of multiple organs often complicates ...
Ahle, Guido, Baraniskin, Alexander, Jähnert, Andreas, Kretzschmar, Hans, Schmiegel, Wolff, Schroers, Roland, Theile, Anja   +6 more
core   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Therapies for Peripheral T-Cell Lymphomas [PDF]

Hematology, 2011
AbstractPeripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of disorders that, for the most part, are associated with a very poor prognosis. The standard therapy for PTCLs is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or a comparable CHOP-like regimen that incorporates anthracyclines.
openaire   +2 more sources

MALT1 proteolytic activity suppresses autoimmunity in a T cell intrinsic manner [PDF]

, 2019
MALT1 is a central signaling component in innate and adaptive immunity by regulating NF-kappa B and other key signaling pathways in different cell types. Activities of MALT1 are mediated by its scaffold and protease functions.
Baens, Mathijs, Beyaert, Rudi, Demeyer, Annelies, Driege, Yasmine, Hochepied, Tino, Kreike, Marja, Skordos, Ioannis, Staal, Jens   +7 more
core   +2 more sources